Atlas Trials

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

Clinical trial NCT03382600 · COMPLETED

Trial details

NCT number
NCT03382600
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2018-03-26
Primary completion
2021-05-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.